# A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT06488716** · PHASE1 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Solid Tumour

## Interventions

- **DRUG:** RO7759065
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT06488716
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-12-16
- **Primary completion:** 2025-11-05
- **Final completion:** 2025-11-05
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Following a thorough review of safety data, preliminary efficacy data and an evaluation of overall risk-benefit, Sponsor made the decision to end the study.
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06488716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06488716, "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06488716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*